The FDA recognizes biomarker development as a high priority area for future research. BBCR can help your company with your product development plan and validation.
Tagged: Biomarker Validation
With Biomarkers now a routine part of drug development, BBCR works with companies in assisting with the identification and adoption of biomarkers, especially valuable in rare disease and precision medicine product development.
June 28th, 2023 | Biomarker ValidationIdentification and adoption of biomarkers are especially valuable in rare disease and precision medicine product development. BBCR can assist in developing your biomarker plan and validation process.
July 8th, 2021 | Biomarker Validation
Biomarkers are now a routine part of drug development In rare diseases and precision medicine, implementation of biomarkers during product translation into clinic and early clinical development, moves treatment to market faster.
Identification and adoption of biomarkers are especially valuable in rare disease and precision medicine product development. Learn more about how BBCR can help.
February 9th, 2021 | Biomarker Validation
Biomarkers are now a routine part of drug development The FDA recognizes biomarker development as a high priority area for future research. The FDA and European Medicines Agency (EMA) have developed similar processes for the qualification of biomarkers intended for use as companion diagnostics or for development and regulatory approval of a drug or therapeutic. […]